Mesoblast Appoints James O'Brien CFO

MT Newswires Live11-17

Mesoblast (MESO) said Monday it has appointed James O'Brien as its chief financial officer.

O'Brien previously worked at different pharmaceutical companies, including Bristol-Myers Squibb (BMY) and Cognition Therapeutics (CGTX), the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment